Log In
BCIQ
Print this Print this
 

aflibercept/rinucumab (REGN2176-3) (formerly REGN-2176)

  Manage Alerts
Collapse Summary General Information
Company Regeneron Pharmaceuticals Inc.
DescriptionCo-formulation of Eylea aflibercept, a human fusion protein that binds all forms of VEGF-A and placental growth factor (PGF; PlGF), and rinucumab, a platelet derived growth factor receptor B (PDGFRB; PDGFR1; CD140B) antibody
Molecular Target Platelet derived growth factor receptor B (PDGFRB) (PDGFR1) (CD140B) ; Placental growth factor (PGF) (PlGF)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat wet age-related macular degeneration (AMD)
Regulatory Designation
PartnerBayer AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$65.0M

$45.5M

$45.0M


 Deals Details
Get a free BioCentury trial today